MedTrace Logo

Effects of Dronabinol (Oral THC) on Cannabis Use

NCT01394185 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-08-03

Study results available
· View outcomes & findings →

Summary

Study participants received dronabinol (0, 120mg/day and 240mg/day) for 12 consecutive days in a randomized order. During each dronabinol maintenance period they were able to self-administer active or placebo cannabis using either a progressive ratio schedule or choice between cannabis and monetary alternative.

Conditions

  • Marijuana Smoking

Interventions

DRUG

Dronabinol 120mg/day

Participants receive 40mg dronabinol 3 times daily

DRUG

Placebo

Participants receive placebo

DRUG

Dronabinol 240mg/day

Participants receive 80mg dronabinol 3 times daily

Sponsors & Collaborators

Principal Investigators

  • Ryan Vandrey, Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01394185 on ClinicalTrials.gov